Although imaging tests revealed stable disease, the patient was switched to S-1 plus nivolumab 3 months before his visit to our hospital because of an increasing trend of tumor marker levels.
← all excerpts
Cytokine release syndrome following COVID-19 infection during treatment with nivolumab for cancer of esophagogastric junction carcinoma: a case report and review.
1
—
—